top of page

3Biotech x Karla Therapeutics



Karla Therapeutics is the first "T cell company" aiming to improve mental health. Its drug development program relies on an immuno-centric approach enabling a precision medicine strategy and having potential applications across various central nervous system (CNS) disorders. Simon LOIODICE, Co-Founder and CEO of Karla Therapeutics, talks about his collaboration with 3Biotech.

In what context and at what stages did 3Biotech intervene in your project?

Karla is a 2022-founded preclinical stage biotech and its most advance candidates are monoclonal antibodies against a novel target. The company managed to generate significant capital traction relatively quickly and was willing to further consolidate its roadmap by building a comprehensive and solid drug development plan up to first-in-human trials. In such context, Karla has requested 3Biotech to help shaping a roadmap (including timelines/budget) focusing on generation/selection of clinical drug candidates, CMC strategy and regulatory aspects that would articulate with the other R&D activities required to progress the program.

How has 3Biotech's approach been innovative and contributed to your success?

It was clear that 3Biotech’s team was very professional and had a significant experience that was not limited to purely technical aspects but also included bio-entrepreneurial expertise and overall understanding of the challenges that an early-stage biotech has to face. This helped 3Biotech to quickly understand (i) Karla’s overall vision and financing/corporate strategy, (ii) the disruptive aspect and potential of Karla’s approach, (iii) the associated challenges and corresponding needs as well as (iv) Karla’s working hypotheses.3Biotech manifested a genuine interest for Karla’s project and worked/brainstormed with the company as a teammate, asking relevant questions, involving relevant experts, and challenging the project to improve its robustness.

What has been the outcome of this collaboration?

The support from 3Biotech helped generating a compelling, realistic, and ambitious plan and value creation strategy with refined timelines, financial needs and milestones hereby supporting discussions with investors as part of Karla’s endeavors in raising capital.

3 key facts about Karla’s project:

  • Lead by an international, experienced, and complementary team (drug development, neuroscience/immunology…)

  • Unique approach to CNS drug development opening to precision medicine strategy.

  • In line with growing evidence pointing the critical role of the neuroimmune axis in CNS disorders.




bottom of page